John P C Le Quesne

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8881710/publications.pdf

Version: 2024-02-01

30 papers 4,964 citations

20 h-index 31 g-index

31 all docs

31 docs citations

times ranked

31

10288 citing authors

#	Article	IF	Citations
1	Statins mediate anti- and pro-tumourigenic functions by remodelling the tumour microenvironment. DMM Disease Models and Mechanisms, 2022, 15, .	2.4	7
2	Inclusion of multiple highâ€risk histopathological criteria improves the prediction of adjuvant chemotherapy efficacy in lung adenocarcinoma. Histopathology, 2021, 78, 838-848.	2.9	9
3	MNK Inhibition Sensitizes <i>KRAS</i> -Mutant Colorectal Cancer to mTORC1 Inhibition by Reducing elF4E Phosphorylation and c-MYC Expression. Cancer Discovery, 2021, 11, 1228-1247.	9.4	45
4	<scp>SOX9</scp> has distinct roles in the formation and progression of different nonâ€small cell lung cancer histotypes. Journal of Pathology, 2021, 255, 16-29.	4.5	5
5	The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer. Nature Communications, 2021, 12, 4651.	12.8	22
6	Analysis of Prostate Cancer Tumor Microenvironment Identifies Reduced Stromal CD4 Effector T-cell Infiltration in Tumors with Pelvic Nodal Metastasis. European Urology Open Science, 2021, 29, 19-29.	0.4	6
7	The pathogenesis of mesothelioma is driven by a dysregulated translatome. Nature Communications, 2021, 12, 4920.	12.8	20
8	Reduced Protumorigenic Tumor-Associated Macrophages With Statin Use in Premalignant Human Lung Adenocarcinoma. JNCI Cancer Spectrum, 2020, 4, pkz101.	2.9	10
9	Nanomolar Protein–Protein Interaction Monitoring with a Label-Free Protein-Probe Technique. Analytical Chemistry, 2020, 92, 15781-15788.	6. 5	15
10	Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. Nature Medicine, 2020, 26, 1054-1062.	30.7	181
11	Repositioning PARP inhibitors for SARSâ€CoVâ€2 infection(COVIDâ€19); a new multiâ€pronged therapy for acute respiratory distress syndrome?. British Journal of Pharmacology, 2020, 177, 3635-3645.	5.4	52
12	IL-4 receptor dependent expansion of lung CD169+ macrophages in microfilaria-driven inflammation. PLoS Neglected Tropical Diseases, 2019, 13, e0007691.	3.0	11
13	In situ growth in early lung adenocarcinoma may represent precursor growth or invasive clone outgrowth—a clinically relevant distinction. Modern Pathology, 2019, 32, 1095-1105.	5.5	17
14	mRNA structural elements immediately upstream of the start codon dictate dependence upon eIF4A helicase activity. Genome Biology, 2019, 20, 300.	8.8	38
15	elF4A2 drives repression of translation at initiation by Ccr4-Not through purine-rich motifs in the 5′UTR. Genome Biology, 2019, 20, 262.	8.8	39
16	eIF4A alleviates the translational repression mediated by classical secondary structures more than by G-quadruplexes. Nucleic Acids Research, 2018, 46, 3075-3087.	14.5	33
17	p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E10869-E10878.	7.1	102
18	The ERBB network facilitates KRAS-driven lung tumorigenesis. Science Translational Medicine, 2018, 10,	12.4	82

#	Article	IF	CITATIONS
19	<i>Ex Vivo</i> Explant Cultures of Non–Small Cell Lung Carcinoma Enable Evaluation of Primary Tumor Responses to Anticancer Therapy. Cancer Research, 2017, 77, 2029-2039.	0.9	64
20	Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. Immunity, 2017, 46, 577-586.	14.3	323
21	Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature, 2017, 545, 446-451.	27.8	1,287
22	Tracking the Evolution of Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 376, 2109-2121.	27.0	1,786
23	Long-Fiber Carbon Nanotubes Replicate Asbestos-Induced Mesothelioma with Disruption of the Tumor Suppressor Gene Cdkn2a (Ink4a/Arf). Current Biology, 2017, 27, 3302-3314.e6.	3.9	96
24	Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. Lancet, The, 2016, 388, 1002-1011.	13.7	132
25	Translational dysregulation in cancer: elF4A isoforms and sequence determinants of elF4A dependence. Biochemical Society Transactions, 2015, 43, 1227-1233.	3.4	55
26	Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study. PLoS Biology, 2014, 12, e1001906.	5.6	185
27	A Comparison of Immunohistochemical Assays and FISH in Detecting the ALK Translocation in Diagnostic Histological and Cytological Lung Tumor Material. Journal of Thoracic Oncology, 2014, 9, 769-774.	1.1	40
28	Dysregulation of protein synthesis and disease. Journal of Pathology, 2010, 220, 140-151.	4.5	72
29	Microâ€RNAs and breast cancer. Molecular Oncology, 2010, 4, 230-241.	4.6	96
30	Identification of a motif that mediates polypyrimidine tract-binding protein-dependent internal ribosome entry. Genes and Development, 2005, 19, 1556-1571.	5.9	110